Oldham Justin M, Kumar Disha, Lee Cathryn, Patel Shruti B, Takahashi-Manns Stephenie, Demchuk Carley, Strek Mary E, Noth Imre
Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL.
Section of Endocrinology, Diabetes, and Metabolism, University of Chicago, Chicago, IL.
Chest. 2015 Sep;148(3):692-700. doi: 10.1378/chest.14-2714.
A significant minority of patients with idiopathic pulmonary fibrosis (IPF) display features of autoimmunity without meeting the criteria for overt connective tissue disease. A link between IPF and other immune-mediated processes, such as hypothyroidism (HT), has not been reported. In this investigation, we aimed to determine whether HT is associated with IPF and if outcomes differ between patients with IPF with and without HT.
A retrospective case-control analysis was conducted. Of 311 patients referred to the University of Chicago Interstitial Lung Disease Center with an initial diagnosis of IPF, 196 met the inclusion criteria and were included in the final analysis. Each case was matched 1:1 by age, sex, and race to a control subject with COPD.
HT was identified in 16.8% of cases and 7.1% of control subjects (OR, 2.7; 95% CI, 1.31-5.54; P = .01). Among patients with IPF, HT was associated with reduced survival time (P < .001) and was found to be an independent predictor of mortality in multivariable Cox regression analysis (hazard ratio, 2.12; 95% CI, 1.31-3.43; P = .002). A secondary analysis of two IPF clinical trial datasets supports these findings.
HT is common among patients with IPF, with a higher prevalence than in those with COPD and the general population. The presence of HT also predicts mortality in IPF, a finding that may improve future prognostication models. More research is needed to determine the biologic link between IPF and HT and how the presence of thyroid disease may influence disease progression.
相当一部分特发性肺纤维化(IPF)患者表现出自身免疫特征,但未达到显性结缔组织病的标准。IPF与其他免疫介导过程(如甲状腺功能减退症(HT))之间的联系尚未见报道。在本研究中,我们旨在确定HT是否与IPF相关,以及IPF合并HT和不合并HT的患者预后是否不同。
进行了一项回顾性病例对照分析。在最初诊断为IPF并转诊至芝加哥大学间质性肺病中心的311例患者中,196例符合纳入标准并纳入最终分析。每个病例按年龄、性别和种族1:1匹配一名慢性阻塞性肺疾病(COPD)对照受试者。
16.8%的病例和7.1%的对照受试者被诊断为HT(比值比,2.7;95%置信区间,1.31 - 5.54;P = 0.01)。在IPF患者中,HT与生存时间缩短相关(P < 0.001),并且在多变量Cox回归分析中被发现是死亡率的独立预测因素(风险比,2.12;95%置信区间,1.31 - 3.43;P = 0.002)。对两个IPF临床试验数据集的二次分析支持了这些发现。
HT在IPF患者中很常见,其患病率高于COPD患者和普通人群。HT的存在也预示着IPF患者的死亡率,这一发现可能会改善未来的预后模型。需要更多的研究来确定IPF与HT之间的生物学联系,以及甲状腺疾病的存在如何影响疾病进展。